1. Home
  2. IDYA vs IMAX Comparison

IDYA vs IMAX Comparison

Compare IDYA & IMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

HOLD

Current Price

$34.91

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo Imax Corporation

IMAX

Imax Corporation

HOLD

Current Price

$44.97

Market Cap

2.2B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDYA
IMAX
Founded
2015
1967
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.2B
IPO Year
2019
1997

Fundamental Metrics

Financial Performance
Metric
IDYA
IMAX
Price
$34.91
$44.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
16
10
Target Price
$52.86
$44.50
AVG Volume (30 Days)
1.2M
882.9K
Earning Date
05-06-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
61.90
31.25
EPS
N/A
0.07
Revenue
$218,710,000.00
$410,212,000.00
Revenue This Year
N/A
$9.79
Revenue Next Year
$201.05
$7.51
P/E Ratio
N/A
$628.57
Revenue Growth
3024.43
16.47
52 Week Low
$20.50
$24.20
52 Week High
$39.28
$45.16

Technical Indicators

Market Signals
Indicator
IDYA
IMAX
Relative Strength Index (RSI) 69.60 73.76
Support Level $32.85 $33.57
Resistance Level $36.01 N/A
Average True Range (ATR) 1.80 1.44
MACD 0.67 0.35
Stochastic Oscillator 92.17 95.97

Price Performance

Historical Comparison
IDYA
IMAX

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About IMAX Imax Corporation

Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.

Share on Social Networks: